Are you a healthcare provider?
This site is intended for U.S. healthcare providers only.
By clicking YES, you attest you are a healthcare provider licensed in the U.S.
IPSEN CARES® (Coverage, Access, Reimbursement & Education Support) serves as a central point of contact between patients, caregivers, doctors’ offices, insurance companies, and specialty pharmacies.
Help patients navigate the insurance coverage process to determine out-of-pocket costs for treatment
Help with copay assistance for eligible* patients
Provide information on Nurse Home Health Administration
Provide free medication to eligible patients through the Patient Assistance Program
Help minimize delays or interruptions to treatment
Coordinate medication deliveries through specialty pharmacies
*Please see Patient Eligibility & Terms and Conditions.
These downloadable resources are intended to provide you and your practice with helpful information.
Listen to diagnostic and treatment advice from key opinion leaders as they discuss hypothetical patient scenarios.
The healthcare professionals in these podcasts are paid consultants for Ipsen.Play Podcast
Pancreatic NET Patient Case StudyDownload
The above case study is hypothetical.
View these videos for insights into specific aspects of Somatuline Depot.
Liquid Crystal Formulation1-4
Learn about the formulation of Somatuline Depot, wherein a high density of nanotubes self-assemble to form a depot that functions as a reservoir for the drug between extended doses.
A demonstration of deep subcutaneous administration technique.
SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.
To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
References: 1. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; 2007. 2. Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Canc. 2016;47(4):366-374. 3. Pandit A, Fay N, Bordes L, et al. Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. J Pept Sci. 2008;14(1):66-75. 4. Somatuline Depot (lanreotide) Injection [Prescribing Information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc.; April 2019.